This study aims to investigate the safety and efficacy of intermittent hypoxia treatment in patients with chronic cerebral hypoperfusion.
Chronic cerebral hypoperfusion is a common and frequently occurring disease in middle-aged and senior people, and an important cause of multiple diseases such as acute ischemic stroke and vascular dementia. However, current treatments for chronic cerebral hypoperfusion are limited and nonspecific. Intermittent hypoxia refers to periodic intervention with alternating normoxia and hypoxia. Studies have shown that short-term (5-10min), low frequency (3-15 times), and mild to moderate hypoxia (9-16%) usually have protective effects and can improve cerebral blood perfusion. Therefore, this study is an exploratory study combining intermittent hypoxia treatment with chronic cerebral hypoperfusion, aiming to preliminarily explore the safety and potential effectiveness of intermittent hypoxia treatment in the using of chronic cerebral hypoperfusion.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
20
The intermittent hypoxia protocol refers to four cycles of 5 minutes hypoxia inhaling interval by 5 minutes normoxia, which is performed twice a day (at least 6 hours apart) in 7 days.
Incidence of adverse reactions
Adverse reactions included headache, vomiting, diarrhea, fatigue, dizziness (according to the Lake Louise scoring system), and insomnia.
Time frame: After the 7-day treatment.
Incidence of adverse reactions
Adverse reactions included headache, vomiting, diarrhea, fatigue, dizziness (according to the Lake Louise scoring system), and insomnia.
Time frame: Thirty days after the treatment.
Tissue oxygen saturation
Including peripheral oxygen saturation and brain tissue oxygen saturation (%).
Time frame: Baseline, after the 7-day treatment, 30 days after the treatment.
Cerebral blood flow
Cerebral blood flow will be detected by transcranial color-coded duplex sonography.
Time frame: Baseline, after the 7-day treatment.
Neurobehavioral scale 1
It is evaluated by scales of Mini-mental State Examination (MMSE), which ranges from 0-30 points, and higher scores mean a worse outcome.
Time frame: Baseline, after the 7-day treatment.
Blood pressure
Including systolic blood pressure and diastolic blood pressure (mmHg).
Time frame: Baseline, after the 7-day treatment, 30 days after the treatment.
Neurobehavioral scale 2
It is evaluated by scales of Montreal Cognitive Assessment (MoCA), which ranges from 0-30 points, and higher scores mean a worse outcome.
Time frame: Baseline, after the 7-day treatment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.